CXC motif ligand 12 as a novel diagnostic marker for papillary thyroid carcinoma

Chung, Soo Young; Park, Eon Sub; Park, So Yeon; Song, Jooyeon; Ryu, Han Suk

doi:10.1002/hed.23404

Cited by 21 publications

(15 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, CK19 seemed to be the weakest marker, as it exhibited the lowest specificity and AUC with respect to diagnosing PTC, likely because its expression rate is extremely high in both benign and malignant thyroid tissue. This finding is consistent with that of a study by Chung et al (30). Previous studies have A and B).…”

Section: Discussionsupporting

confidence: 94%

CIP2A is a poor prognostic factor and can be a diagnostic marker in papillary thyroid carcinoma

Chao

Maa

Chen

et al. 2016

APMIS

View full text Add to dashboard Cite

Papillary thyroid carcinoma (PTC) is the most common type of thyroid carcinoma. CIP2A has recently been described as a prognostic marker in many cancers. In this study, we assessed the value of this novel prognostic marker in PTC. A total of 178 surgical specimens of both benign and malignant thyroid tumors were collected. Immunohistochemical staining for CIP2A, HBME-1, galectin-3, and CK19 was performed. Western blotting for CIP2A was also performed. CIP2A was expressed in 85.3% of malignant tumors and 12.1% of benign tumors. ROC analysis showed that the AUC for CIP2A was higher than those for other tumor markers. Western blotting showed that CIP2A expression was higher in PTC than in other tumors. Poor progression-free survival was observed in the high-CIP2A expression group. High CIP2A expression is a poor prognostic factor and can be a diagnostic marker in PTC. The presence of any two of the three indicated makers (CIP2A, galectin-3, and HBME-1) is strongly correlated with the diagnosis of PTC.

show abstract

Section: Discussionsupporting

confidence: 94%

CIP2A is a poor prognostic factor and can be a diagnostic marker in papillary thyroid carcinoma

Chao

Maa

Chen

et al. 2016

APMIS

View full text Add to dashboard Cite

show abstract

“…These findings indicate that CXCL12 may be an effective biomarker for PTC. Consistently, Chung et al ( 20 ) recently demonstrated that CXCL12 was exclusively overexpressed in human PTC regardless of histological subtypes compared with non-cancerous thyroid lesions, and the sensitivity and specificity of using CXCL12 as a diagnostic marker for PTC was 90.8 and 96.8%, respectively ( 20 ). Jung et al ( 21 ) also reported that 90% of follicular PTC specimens were positive for CXCL12, whereas only 10.5% of follicular thyroid neoplasm specimens showed positive CXCL12.…”

Section: Discussionmentioning

confidence: 72%

“…Strong CXCR7 expression has been found in tumor-associated blood vessels in breast and lung cancer tissue but not on normal vasculature ( 19 ). In thyroid cancer, the expressions of CXCL12, CXCR4 and CXCR7 have also been detected in cancer tissue ( 20 – 23 ). However, the contribution of CXCL12/CXCR4/CXCR7 axis to thyroid cancer progression and the possible CXCR4-mediated signaling pathways in thyroid cancer cells remain unclear.…”

Section: Introductionmentioning

confidence: 99%

Expression and function of CXCL12/CXCR4/CXCR7 in thyroid cancer

Zhu

Bai

et al. 2016

International Journal of Oncology

View full text Add to dashboard Cite

The contribution of CXCL12/CXCR4/CXCR7 axis to cancer progression has been increasingly recognized. However, its role in thyroid cancer development remains unclear. The present study aimed to examine the expression and function of CXCL12 and its receptors in thyroid cancer. The expression of CXCL12/CXCR4/CXCR7 in human tissue specimens of papillary, follicular, medullary, and anaplastic thyroid carcinoma, follicular adenoma, Hashimoto's thyroiditis and nodular goiter were examined by immunohistochemistry using a tissue microarray. CXCR4 and CXCR7 were over-expressed in human thyroid cancer cells K1 by transduction of recombinant lentivirus. The effect of overexpression of CXCR4 and CXCR7 on K1 cell proliferation and invasion and the molecular mechanism underlying the effect were investigated. CXCL12 was exclusively expressed in papillary thyroid carcinoma tissue but absent in other types of thyroid malignancies and benign lesions. CXCR7 was widely expressed in the endothelial cells of all types of malignancy but only occasionally detected in benign lesions. CXCR4 was expressed in 62.5% of papillary thyroid carcinoma tissue specimens and in 30–40% of other types of malignancy, and it was either absent or weakly expressed in benign lesions. CXCL12 stimulated the invasion and migration of K1 cells overexpressing CXCR4, but did not affect K1 cells overexpressing CXCR7. K1 cell proliferation was not affected by overexpression of CXCR4 or CXCR7. Overexpression of CXCR4 in K1 cells significantly increased AKT and ERK phosphorylation and markedly induced the expression and activity of matrix metalloproteinase-2 (MMP-2). Thus, CXCL12 may be an effective diagnostic marker for papillary thyroid carcinoma, and CXCL12/CXCR4/CXCR7 axis may contribute to thyroid cancer development by regulating cancer cell migration and invasion via AKT and ERK signaling and MMP-2 activation.

show abstract

“…CXC motif ligand 12, also known as stromal cell-derived factor-1, binds to the CXCR4 ( 39 ) and to the CXCR7 receptors ( 59 , 60 ). CXCL12 displays a strong chemotactic power toward lymphocytes, and it is known to play an important role in angiogenesis and tumor cell migration ( 39 ). The expression of CXCL12, CXCR4, and CXCR7 was detected in thyroid cancer tissue specimens ( 39 , 61 – 63 ).…”

Section: Thyroid Cancermentioning

confidence: 99%

Role of Chemokines in Thyroid Cancer Microenvironment: Is CXCL8 the Main Player?

et al. 2018

View full text Add to dashboard Cite

Tumor-related inflammation does influence the biological behavior of neoplastic cells and ultimately the patient’s outcome. With specific regard to thyroid cancer, the issue of tumor-associated inflammation has been extensively studied and recently reviewed. However, the role of chemokines, which play a crucial role in determining the immuno-phenotype of tumor-related inflammation, was not addressed in previous reviews on the topic. Experimental evidence shows that thyroid cancer cells actively secrete a wide spectrum of chemokines and, at least for some of them, solid scientific data support a role for these immune-active molecules in the aggressive behavior of the tumor. Our proposal for a review article on chemokines and thyroid cancer stems from the notion that chemokines, besides having the ability to attract and maintain immune cells at the tumor site, also produce several pro-tumorigenic actions, which include proangiogenetic, cytoproliferative, and pro-metastatic effects. Studies taking into account the role of CCL15, C–X–C motif ligand 12, CXCL16, CXCL1, CCL20, and CCL2 in the context of thyroid cancer will be reviewed with particular emphasis on CXCL8. The reason for focusing on CXCL8 is that this chemokine is the most studied one in human malignancies, displaying multifaceted pro-tumorigenic effects. These include enhancement of tumor cells growth, metastatization, and angiogenesis overall contributing to the progression of several cancers including thyroid cancer. We aim at reviewing current knowledge on the (i) ability of both normal and tumor thyroid cells to secrete CXCL8; (ii) direct/indirect pro-tumorigenic effects of CXCL8 demonstrated by in vitro and in vivo studies specifically performed on thyroid cancer cells; and (iii) pharmacologic strategies proven to be effective for lowering CXCL8 secretion and/or its effects on thyroid cancer cells.

show abstract

CXC motif ligand 12 as a novel diagnostic marker for papillary thyroid carcinoma

Abstract: Our findings indicate that CXCL12 might serve as an effective novel supplementary diagnostic marker for PTC.

Cited by 21 publications

References 28 publications

CIP2A is a poor prognostic factor and can be a diagnostic marker in papillary thyroid carcinoma

CIP2A is a poor prognostic factor and can be a diagnostic marker in papillary thyroid carcinoma

Expression and function of CXCL12/CXCR4/CXCR7 in thyroid cancer

Role of Chemokines in Thyroid Cancer Microenvironment: Is CXCL8 the Main Player?

Contact Info

Product

Resources

About